United Kingdom
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Sterling Pharma Solutions.
Kivu Bioscience, a biotech company developing next-gen antibody-drug conjugates (ADCs), entered a manufacturing agreement with Sterling Pharma Solutions, a global CDMO, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology ADC candidate, KIVU-107.
Sterling will manufacture cGMP clinical material for KIVU-107 at its dedicated bioconjugation facility in Deeside, UK. The collaboration includes process familiarization, analytical development, process optimization, and scale-up activities in preparation for a cGMP manufacturing campaign.
North East based Sterling Environmental Solutions, part of Sterling Pharma Solutions, has commissioned an £8m anaerobic digestion (AD) plant, which is the first of it’s kind in the UK, supporting the company’s aim for carbon neutrality.
Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has completed the acquisition of UK-based NewChem Technologies, a contract services provider focused on organic chemistry and supplying customers across a range of industries from pharmaceuticals, diagnostics and biotechnology to veterinary science and chemicals.
London, UK – 25 May 2023: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, and Partners Group, a leading global private markets firm, acting on behalf of its clients, today announce an investment in GHO portfolio company Sterling Pharma Solutions (“Sterling” or “the Company”), a global Contract Development and Manufacturing Organisation (“CDMO”).
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has commenced production of hydroxychloroquine (HCQ), a treatment currently under investigation for COVID-19.
Sterling will be manufacturing the active pharmaceutical ingredient (API) with the finished product being manufactured and supplied by Accord Healthcare.
The UK’s current supply of HCQ is sourced from overseas, primarily as a result of economic pressures driving production to lower cost manufacturing regions. This new deal with Accord will establish a domestic supply of the product ensuring access for patients in the UK, should the drug prove successful.
Kevin Cook CEO at Sterling Pharma Solutions said, “While it is currently unclear whether HCQ will be a viable treatment for COVID-19, it is vital to proactively establish a strong supply route ahead of time.
“Rapid response to a rapidly changing landscape has been key here. We have worked quickly alongside Accord Healthcare to establish a UK supply chain for this product.
“HCQ could potentially provide an effective treatment for COVID patients and during such an unprecedented time it’s important that the pharmaceutical industry works flexibly to achieve maximum results as quickly as possible and this partnership is a good example of that.”
Sterling has already supported Accord with the purchase of over 50 tonnes of the key raw materials, which equates to roughly 60 million finished tablets of HCQ.
As a result of the partnership Accord expects to supply up to 50 million HCQ tablets per month and has already started production of HCQ from its manufacturing facility in Barnstable, UK.
This is the News section of the company profile page for Sterling Pharma Solutions on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
